Vanda Pharmaceuticals develops and commercializes therapies for unmet medical needs worldwide. Marketed products include HETLIOZ for sleep disorders and Fanapt for schizophrenia. Pipeline products include HETLIOZ for jet lag, insomnia, and autism; Fanapt for bipolar disorder and Parkinsons disease psychosis; and Tradipitant for gastroparesis, motion sickness, and atopic dermatitis. The company also has pipeline products VTR-297, VQW-765, VHX-896, and antisense oligonucleotide molecules. In addition, it offers cystic fibrosis transmembrane conductance regulator activators and inhibitors for dry eye and secretory diarrhea disorders. The company was incorporated in 2002 and is headquartered in Washington, D.C.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 2.8 |